Fecal microbiota transplantation combined with anti-PD-1 therapy in refractory microsatellite-stable gastric cancer: a phase I feasibility and safety study - PubMed
4 hours ago
- #Gastric Cancer
- #Immunotherapy
- #Fecal Microbiota Transplantation
- Study evaluates fecal microbiota transplantation (FMT) combined with anti-PD-1 therapy in refractory microsatellite-stable gastric cancer.
- Phase I open-label, single-arm study involving 10 patients with advanced GI cancer resistant to anti-PD-(L)1 treatment.
- Patients received FMT via oral capsules followed by combination therapy with nivolumab.
- Combination therapy was well-tolerated with no serious adverse events.
- Objective response rate was 20%, disease control rate was 40%.
- Clinical benefits linked to donor-derived immunogenic microbes and activated immune status.
- Microbial signatures for anti-PD-1 responsiveness were identified and validated.
- Findings support feasibility and safety of FMT with anti-PD-1 therapy in ICI-refractory gastric cancer.